Chordate Medical Holding ABs (publ) set-off share issue is now registered

Chordate Medical Holding AB (publ) ("Chordate Medical" or the "Company") announces that the directed set-off issue to underwriters who have chosen to receive guarantee compensation in the form of newly issued shares in the Company announced on January 18, 2023 (the "Compensation Issue") has been registered with the Swedish Companies Registration Office (sw. “Bolagsverket”). Distribution of shares is expected to commence on January 25, 2023.

Financial and legal advisers

Västra Hamnen Corporate Finance AB acts as financial adviser and Wistrand Advokatbyrå acts as legal adviser to Chordate Medical in connection with the Compensation Issue.

The information was submitted, through the contact person above, for publication on January 24 at 19.20 2023 (CET).

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact